Combination Therapy for Stage IIA-IIIB Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have untreated stage IIA to IIIB non-small cell lung cancer (confirmed by biopsy).
- Your lung tumor can be removed or possibly removed with surgery (as decided by a team of doctors).
- You have at least one tumor that can be measured on scans (like CT or MRI).
- You have a tumor tissue sample available for PD-L1 testing.
- You do not have an EGFR gene change or ALK fusion, and have not had immunotherapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation therapy, an immunotherapy drug (tislelizumab), and chemotherapy to shrink bulky stage III lung cancer before possible surgery. The goal is to see if this approach is safe and effective.
This trial tests a new combination of radiation, immunotherapy, and chemotherapy given before surgery for stage II or III lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of radiation, an immunotherapy drug called tislelizumab, and chemotherapy given before surgery for non-small cell lung cancer that has not spread too far (stage II-III). The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether a special type of focused radiation therapy can effectively treat advanced non-small cell lung cancer (the most common type) as an upfront treatment. It may help patients avoid or delay chemotherapy while controlling their cancer.
This trial tests combining a type of radiation therapy called SBRT with an immunotherapy drug called puterizumab for patients whose non-small cell lung cancer has spread to the lungs after prior immunotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a new treatment combining stereotactic radiation (SFRT), the immunotherapy tislelizumab, and platinum chemotherapy for people with stage III non-small cell lung cancer that can't be removed with surgery. It aims to see if this combination helps shrink or control the cancer better.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.